Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 5 (May)

1. Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng.
   Arch Pharm Res, 32(4): 505-13. [Abstract] [Full-text]
2. Gram-negative bloodstream infections in hematopoietic stem cell transplant patients: the roles of needleless device use, bathing practices, and catheter care.
   Am J Infect Control, 37(4): 327-34. [Abstract] [Full-text]
3. Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
   Cancer Chemother Pharmacol, 64(1): 199-200. [Abstract] [Full-text]
4. International prognostic scoring system for Waldenstrom macroglobulinemia.
   Blood, 113(18): 4163-70. [Abstract] [Full-text]
5. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
   Blood, 113(18): 4137-43. [Abstract] [Full-text]
6. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
   Blood, 113(18): 4391-402. [Abstract] [Full-text]
7. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.
   Blood, 113(18): 4179-87. [Abstract] [Full-text]
8. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
   Cancer Chemother Pharmacol, 64(1): 161-7. [Abstract] [Full-text]
9. Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma.
   Cancer Chemother Pharmacol, 64(1): 109-14. [Abstract] [Full-text]
10. A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 64(1): 73-8. [Abstract] [Full-text]
11. Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
    Cancer Chemother Pharmacol, 64(1): 67-72. [Abstract] [Full-text]
12. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
    Cancer Chemother Pharmacol, 64(1): 45-51. [Abstract] [Full-text]
13. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
    Cancer Chemother Pharmacol, 64(1): 27-33. [Abstract] [Full-text]
14. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
    Lancet, 373(9674): 1525-31. [Abstract] [Full-text]
15. Unguided sacroiliac injection: effect on refractory buttock pain in patients with spondyloarthropathies.
    Presse Med, 38(5): 710-6. [Abstract] [Full-text]
16. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
    Cancer, 115(10): 2119-27. [Abstract] [Full-text]
17. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
    Cancer, 115(10): 2147-54. [Abstract] [Full-text]
18. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
    Cancer, 115(10): 2165-76. [Abstract] [Full-text]
19. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
    Cancer, 115(10): 2138-46. [Abstract] [Full-text]
20. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.
    Cancer, 115(10): 2041-51. [Abstract] [Full-text]
21. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
    Cancer, 115(10): 2188-98. [Abstract] [Full-text]
22. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.
    Cancer, 115(10): 2155-64. [Abstract] [Full-text]
23. Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer.
    Eur J Surg Oncol, 35(6): 583-7. [Abstract] [Full-text]
24. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
    Int J Cancer, 125(1): 1-8. [Abstract] [Full-text]
25. Osteoblastic bone formation is induced by using nanogel-crosslinking hydrogel as novel scaffold for bone growth factor.
    J Cell Physiol, 220(1): 1-7. [Abstract] [Full-text]
26. Varicella zoster exposure on paediatric wards between 2000 and 2007: safe and effective post-exposure prophylaxis with oral aciclovir.
    J Hosp Infect, 72(2): 163-8. [Abstract] [Full-text]
27. Fatal Aspergillus rhinosinusitis during induction chemotherapy in a child with acute lymphoblastic leukemia.
    J Pediatr Hematol Oncol, 31(5): 367-9. [Abstract] [Full-text]
28. From upfront nephrectomy to preoperative chemotherapy and back: a single institution experience in the treatment of Wilms tumor.
    J Pediatr Hematol Oncol, 31(5): 333-8. [Abstract] [Full-text]
29. Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in cisplatin-refractory germ cell tumor.
    South Med J, 102(5): 546-8. [Abstract] [Full-text]
30. Major amputation for irresectable extremity melanoma after failure of isolated limb infusion.
    Ann Surg Oncol, 16(6): 1543-7. [Abstract] [Full-text]
31. Multiscale modeling framework of transdermal drug delivery.
    Ann Biomed Eng, 37(6): 1217-29. [Abstract] [Full-text]
32. Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia.
    Leuk Res, 33(7): 898-901. [Abstract] [Full-text]
33. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia.
    Leuk Res, 33(7): 1001-4. [Abstract] [Full-text]
34. Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures.
    Leuk Res, 33(7): 997-1000. [Abstract] [Full-text]
35. Quantitative and qualitative control of cytotoxic preparations by HPLC-UV in a centralized parenteral preparations unit.
    J Pharm Biomed Anal, 49(5): 1213-20. [Abstract] [Full-text]
36. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    J Natl Cancer Inst, 101(9): 644-50. [Abstract] [Full-text]
37. Thrombolytic therapy in central retinal artery occlusion: cutting edge therapy, standard of care therapy, or impractical therapy?
    Curr Opin Ophthalmol, 20(3): 210-8. [Abstract] [Full-text]
38. Bursting of sensitive polymersomes induced by curling.
    Proc Natl Acad Sci U S A, 106(18): 7294-8. [Abstract] [Full-text]
39. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series.
    Clin Infect Dis, 48(11): e96-107. [Abstract] [Full-text]
40. Availability of HIV postexposure prophylaxis services in Los Angeles County.
    Clin Infect Dis, 48(11): 1624-7. [Abstract] [Full-text]
41. Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy.
    Clin Infect Dis, 48(11): 1516-25. [Abstract] [Full-text]
42. Mu2-alkyne dicobalt(0)hexacarbonyl complexes as carbon monoxide-releasing molecules (CO-RMs): probing the release mechanism.
    Dalton Trans. [Abstract] [Full-text]
43. In vitro heavy-atom effect of palladium(II) and platinum(II) complexes of pyrrolidine-fused chlorin in photodynamic therapy.
    J Med Chem, 52(9): 2747-53. [Abstract] [Full-text]
44. Modified-release hydrocortisone to provide circadian cortisol profiles.
    J Clin Endocrinol Metab, 94(5): 1548-54. [Abstract] [Full-text]
45. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients.
    J Clin Endocrinol Metab, 94(5): 1623-9. [Abstract] [Full-text]
46. Acetylation of PAMAM dendrimers for cellular delivery of siRNA.
    BMC Biotechnol, 9: 38. [Abstract] [Full-text]
47. Medication Administration Time Study (MATS): nursing staff performance of medication administration.
    J Nurs Adm, 39(5): 204-10. [Abstract] [Full-text]
48. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.
    J Surg Oncol, 99(7): 409-13. [Abstract] [Full-text]
49. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers.
    Gynecol Oncol, 113(3): 327-30. [Abstract] [Full-text]
50. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
    Eur J Haematol, 82(6): 426-32. [Abstract] [Full-text]
51. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
    Int J Radiat Oncol Biol Phys, 74(2): 433-9. [Abstract] [Full-text]
52. Enhancement of esculetin on arsenic trioxide-provoked apoptosis in human leukemia U937 cells.
    Chem Biol Interact, 180(1): 61-8. [Abstract] [Full-text]
53. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury.
    Biochem Pharmacol, 77(12): 1763-72. [Abstract] [Full-text]
54. Safety and benefit of early elective percutaneous coronary intervention after successful thrombolytic therapy for acute myocardial infarction.
    Am J Cardiol, 103(10): 1333-8. [Abstract] [Full-text]
55. Nanoparticle-based targeted drug delivery.
    Exp Mol Pathol, 86(3): 215-23. [Abstract] [Full-text]
56. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
    J Urol, 181(6): 2476-80; discussion 2480-1. [Abstract] [Full-text]
57. Calcium phosphate nanoparticles as efficient carriers for photodynamic therapy against cells and bacteria.
    Biomaterials, 30(19): 3324-31. [Abstract] [Full-text]
58. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
    Biomaterials, 30(19): 3297-306. [Abstract] [Full-text]
59. Development of polyion complex micelles for encapsulating and delivering amphotericin B.
    Biomaterials, 30(19): 3352-8. [Abstract] [Full-text]
60. Antibiotic delivery system using nano-hydroxyapatite/chitosan bone cement consisting of berberine.
    J Biomed Mater Res A, 89(4): 1108-17. [Abstract] [Full-text]
61. Preparation and evaluation of chitosan-ethylenediaminetetraacetic acid hydrogel films for the mucoadhesive transbuccal delivery of insulin.
    J Biomed Mater Res A, 89(4): 1063-71. [Abstract] [Full-text]
62. Temperature sensitivity and drug encapsulation of star-shaped amphiphilic block copolymer based on dendritic poly(ether-amide).
    J Biomed Mater Res A, 89(4): 988-1000. [Abstract] [Full-text]
63. Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery.
    J Biomed Mater Res A, 89(4): 876-84. [Abstract] [Full-text]
64. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study.
    Eur J Endocrinol, 160(6): 979-83. [Abstract] [Full-text]
65. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone.
    Eur J Endocrinol, 160(6): 993-1002. [Abstract] [Full-text]
66. Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy.
    Eur J Endocrinol, 160(6): 919-24. [Abstract] [Full-text]
67. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
    J Antimicrob Chemother, 63(6): 1251-5. [Abstract] [Full-text]
68. Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
    Br J Cancer, 100(10): 1581-8. [Abstract] [Full-text]
69. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.
    Br J Cancer, 100(10): 1647-58. [Abstract] [Full-text]
70. Targeting HSP90 for cancer therapy.
    Br J Cancer, 100(10): 1523-9. [Abstract] [Full-text]
71. Molecular classification of solid tumours: towards pathway-driven therapeutics.
    Br J Cancer, 100(10): 1517-22. [Abstract] [Full-text]
72. Plasma heparanase as a significant marker of treatment response in children with Hodgkin lymphoma: pilot study.
    Pediatr Hematol Oncol, 26(4): 157-64. [Abstract] [Full-text]
73. Adjuvant chemotherapy in older women with early-stage breast cancer.
    N Engl J Med, 360(20): 2055-65. [Abstract] [Full-text]
74. Estradiol reverses a calcium-related biomarker of brain aging in female rats.
    J Neurosci, 29(19): 6058-67. [Abstract] [Full-text]
75. Diffusion-limited binding explains binary dose response for local arterial and tumour drug delivery.
    Cell Prolif, 42(3): 348-63. [Abstract] [Full-text]
76. Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy.
    Pediatr Blood Cancer, 53(1): 23-7. [Abstract] [Full-text]
77. Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi.
    Pediatr Blood Cancer, 53(1): 47-52. [Abstract] [Full-text]
78. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
    Pediatr Blood Cancer, 53(1): 33-6. [Abstract] [Full-text]
79. Negative correlation between cerebrospinal fluid tau protein and cognitive functioning in children with acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 53(1): 105-8. [Abstract] [Full-text]
80. Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
    Pediatr Blood Cancer, 53(1): 37-41. [Abstract] [Full-text]
81. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.
    Pediatr Blood Cancer, 53(1): 17-22. [Abstract] [Full-text]
82. Perspectives on the American College of Cardiology/American Heart Association guidelines for the prevention of infective endocarditis.
    J Am Coll Cardiol, 53(20): 1852-4. [Abstract] [Full-text]
83. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.
    Blood, 113(20): 4875-84. [Abstract] [Full-text]
84. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
    Blood, 113(20): 4885-93. [Abstract] [Full-text]
85. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
    Blood, 113(20): 4841-52. [Abstract] [Full-text]
86. An injectable, in situ enzymatically gellable, gelatin derivative for drug delivery and tissue engineering.
    Biomaterials, 30(20): 3371-7. [Abstract] [Full-text]
87. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
    Biomaterials, 30(20): 3476-85. [Abstract] [Full-text]
88. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers.
    Biomaterials, 30(20): 3466-75. [Abstract] [Full-text]
89. Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.
    Anesth Analg, 108(6): 1984-6. [Abstract] [Full-text]
90. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy.
    Metabolism, 58(6): 854-9. [Abstract] [Full-text]
91. Preprinted order sets as a safety intervention in pediatric sedation.
    J Pediatr, 154(6): 865-8. [Abstract] [Full-text]
92. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
    Leuk Res, 33(8): 1096-9. [Abstract] [Full-text]
93. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
    Leuk Res, 33(8): 1072-8. [Abstract] [Full-text]
94. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
    Leuk Res, 33(8): 1055-61. [Abstract] [Full-text]
95. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
    Oncology, 76(6): 442-6. [Abstract] [Full-text]
96. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
    J Clin Oncol, 27(15): 2516-22. [Abstract] [Full-text]
97. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
    J Clin Oncol, 27(15): 2429-35. [Abstract] [Full-text]
98. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    J Clin Oncol, 27(15): 2457-65. [Abstract] [Full-text]
99. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
    J Clin Oncol, 27(15): 2436-42. [Abstract] [Full-text]
100. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
     J Clin Oncol, 27(15): 2536-41. [Abstract] [Full-text]
101. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
     J Clin Oncol, 27(15): 2530-5. [Abstract] [Full-text]
102. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
     J Clin Oncol, 27(15): 2474-81. [Abstract] [Full-text]
103. Is nitric oxide important in photodynamic therapy?
     J Photochem Photobiol B, 95(3): 141-7. [Abstract] [Full-text]
104. Characterization of chemopreventive agents from the dichloromethane extract of Eurycorymbus cavaleriei by liquid chromatography-ion trap mass spectrometry.
     J Chromatogr A, 1216(24): 4859-67. [Abstract] [Full-text]
105. Aberration of the enzymatic activity of Fhit tumor suppressor protein enhances cancer cell death upon photodynamic therapy similarly to that driven by wild-type Fhit.
     Cancer Lett, 280(1): 101-9. [Abstract] [Full-text]
106. Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens.
     Gastroenterology, 136(6): 1952-65. [Abstract] [Full-text]
107. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium.
     Arterioscler Thromb Vasc Biol, 29(6): 796-801. [Abstract] [Full-text]
108. Testosterone replacement does not normalize carcass composition in chronically decerebrate male rats.
     Am J Physiol Regul Integr Comp Physiol, 296(6): R1687-94. [Abstract] [Full-text]
109. Drinking-induced thermoregulatory panting in rehydrated sheep: influences of oropharyngeal/esophageal signals, core temperature, and thirst satiety.
     Am J Physiol Regul Integr Comp Physiol, 296(6): R1881-8. [Abstract] [Full-text]
110. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.
     Ann Hematol, 88(7): 613-21. [Abstract] [Full-text]
111. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
     Ann Hematol, 88(7): 639-45. [Abstract] [Full-text]
112. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
     Ann Hematol, 88(7): 633-7. [Abstract] [Full-text]
113. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression.
     J Infect Dis, 199(12): 1872-82. [Abstract] [Full-text]
114. Parental reporting of suspected adverse drug reactions in children in Lagos, Nigeria.
     Arch Dis Child, 94(6): 469-73. [Abstract] [Full-text]
115. Mechanical approaches combined with intra-arterial pharmacological therapy are associated with higher recanalization rates than either intervention alone in revascularization of acute carotid terminus occlusion.
     Stroke, 40(6): 2092-7. [Abstract] [Full-text]
116. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale.
     Stroke, 40(6): 2079-84. [Abstract] [Full-text]
117. Thrombolysis in young adults with ischemic stroke.
     Stroke, 40(6): 2085-91. [Abstract] [Full-text]
118. Pemetrexed in first-line treatment of non-small cell lung cancer.
     Cancer Treat Rev, 35(4): 364-73. [Abstract] [Full-text]
119. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.
     Am J Ophthalmol, 147(6): 1048-54, 1054.e1-2. [Abstract] [Full-text]
120. Magnesium and tumors: ally or foe?
     Cancer Treat Rev, 35(4): 378-82. [Abstract] [Full-text]
121. Therapeutic options for elderly patients with advanced non-small cell lung cancer.
     Cancer Treat Rev, 35(4): 340-4. [Abstract] [Full-text]
122. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.
     Cancer Treat Rev, 35(4): 309-21. [Abstract] [Full-text]
123. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
     Cancer Treat Rev, 35(4): 335-9. [Abstract] [Full-text]
124. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
     J Acquir Immune Defic Syndr, 51(2): 140-6. [Abstract] [Full-text]
125. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
     J Acquir Immune Defic Syndr, 51(2): 224-30. [Abstract] [Full-text]
126. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy.
     J Acquir Immune Defic Syndr, 51(2): 111-6. [Abstract] [Full-text]
127. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.
     Ann Oncol, 20(6): 1062-7. [Abstract] [Full-text]
128. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
     Ann Oncol, 20(6): 1068-73. [Abstract] [Full-text]
129. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
     Ann Oncol, 20(6): 1074-9. [Abstract] [Full-text]
130. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.
     Ann Oncol, 20(6): 1057-61. [Abstract] [Full-text]
131. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
     Ann Oncol, 20(6): 1042-7. [Abstract] [Full-text]
132. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.
     Ann Oncol, 20(6): 985-92. [Abstract] [Full-text]
133. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
     Ann Oncol, 20(6): 1048-56. [Abstract] [Full-text]
134. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles.
     Biomaterials, 30(21): 3614-25. [Abstract] [Full-text]
135. Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent.
     Biomaterials, 30(21): 3588-96. [Abstract] [Full-text]
136. Block-copolymer micelles as carriers of cell signaling modulators for the inhibition of JNK in human islets of Langerhans.
     Biomaterials, 30(21): 3597-604. [Abstract] [Full-text]
137. Synthesis and anaerobic biodegradation of indomethacin-conjugated cellulose ethers used for colon-specific drug delivery.
     Bioresour Technol, 100(18): 4164-70. [Abstract] [Full-text]
138. Prescription errors and outcomes related to inconsistent information transmitted through computerized order entry: a prospective study.
     Arch Intern Med, 169(10): 982-9. [Abstract] [Full-text]
139. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone.
     Br J Ophthalmol, 93(6): 754-8. [Abstract] [Full-text]
140. Photodynamic effect of hypericin in primary cultures of human umbilical endothelial cells and glioma cell lines.
     Phytother Res, 23(6): 827-32. [Abstract] [Full-text]
141. Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel.
     Arch Pharm Res, 32(5): 755-65. [Abstract] [Full-text]
142. Enhanced transdermal absorption and pharmacokinetic evaluation of pranoprofen-ethylene-vinyl acetate matrix containing penetration enhancer in rats.
     Arch Pharm Res, 32(5): 747-53. [Abstract] [Full-text]
143. Effects of the menopause transition and hormone use on cognitive performance in midlife women.
     Neurology, 72(21): 1850-7. [Abstract] [Full-text]
144. When should we perform prophylactic antibiotics in elective cesarean cases?
     Arch Gynecol Obstet, 280(1): 13-8. [Abstract] [Full-text]
145. Low-frequency and high-intensity ultrasonic may play a better role in Ultrasound Contrast Agent drug delivery system in vivo.
     Med Hypotheses, 73(2): 211-2. [Abstract] [Full-text]
146. Cancer's craving for sugar: an opportunity for clinical exploitation.
     J Cancer Res Clin Oncol, 135(7): 867-77. [Abstract] [Full-text]
147. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
     Clin Infect Dis, 48(12): 1752-9. [Abstract] [Full-text]
148. Gastric cancer in the era of molecularly targeted agents: current drug development strategies.
     J Cancer Res Clin Oncol, 135(7): 855-66. [Abstract] [Full-text]
149. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
     Radiology, 251(3): 653-62. [Abstract] [Full-text]
150. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel.
     J Cancer Res Clin Oncol, 135(7): 901-8. [Abstract] [Full-text]
151. A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
     Breast Cancer Res Treat, 115(3): 609-12. [Abstract] [Full-text]
152. Impact on rates and time to first central vascular-associated bloodstream infection when switching from open to closed intravenous infusion containers in a hospital setting.
     Epidemiol Infect, 137(7): 1041-8. [Abstract] [Full-text]
153. Can cetuximab affect paraneoplastic myopathy?
     J Neurooncol, 93(3): 437-8. [Abstract] [Full-text]
154. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
     J Neurooncol, 93(3): 409-12. [Abstract] [Full-text]
155. Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
     Cancer Invest, 27(5): 521-8. [Abstract] [Full-text]
156. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
     J Clin Oncol, 27(16): 2668-76. [Abstract] [Full-text]
157. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.
     J Clin Oncol, 27(16): 2592-7. [Abstract] [Full-text]
158. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
     J Clin Oncol, 27(16): 2622-9. [Abstract] [Full-text]
159. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
     J Clin Oncol, 27(16): 2630-7. [Abstract] [Full-text]
160. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
     J Clin Oncol, 27(16): 2638-44. [Abstract] [Full-text]
161. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
     Blood, 113(22): 5549-57. [Abstract] [Full-text]
162. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
     J Clin Oncol, 27(16): 2598-603. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.